Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Rajkumar

Showing results (461-470 of 602) with videos related to

Pageof 61
Sort By:
American Journal of Hematology|October 4, 2025
Clinical Characteristics, Treatment Responses and Outcomes of Light Chain Multiple MyelomaAbiola Bolarinwa, Saurabh Zanwar, Nadine Abdallah, et al.
Blood Advances|January 30, 2025
Solitary plasmacytoma: single-institution experience, and systematic review and meta-analysis of clinical outcomesCharalampos Charalampous, Jean-Sebastien Claveau, Prashant Kapoor, et al.
Blood Cancer Journal|December 13, 2018
Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcomeAshley R Paquin, Shaji K Kumar, Francis K Buadi, et al.
American Journal of Hematology|September 9, 2018
Utility and prognostic value of <sup>18</sup> F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myelomaMohammed A Aljama, M Hasib Sidiqi, Francis K Buadi, et al.
Blood|March 28, 2009
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasonePrashant Kapoor, Shaji Kumar, Rafael Fonseca, et al.
Leukemia|July 31, 2020
Correction: Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosisEli Muchtar, Morie A Gertz, Taxiarchis V Kourelis, et al.
European Journal of Haematology|March 8, 2020
c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myelomaAlessandra Di Bacco, Nizar J Bahlis, Nikhil C Munshi, et al.
American Journal of Hematology|December 29, 2018
Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry methodSurbhi Sidana, Dragan Jevremovic, Rhett P Ketterling, et al.
Blood|October 22, 2017
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patientsHervé Avet-Loiseau, Nizar J Bahlis, Wee-Joo Chng, et al.
Blood|January 28, 2017
Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early deathEli Muchtar, Morie A Gertz, Shaji K Kumar, et al.
Pageof 61

Showing results (461-470 of 602) with videos related to

Sort By:
Pageof 61
American Journal of Hematology|October 4, 2025
Clinical Characteristics, Treatment Responses and Outcomes of Light Chain Multiple MyelomaAbiola Bolarinwa, Saurabh Zanwar, Nadine Abdallah, et al.
Blood Advances|January 30, 2025
Solitary plasmacytoma: single-institution experience, and systematic review and meta-analysis of clinical outcomesCharalampos Charalampous, Jean-Sebastien Claveau, Prashant Kapoor, et al.
Blood Cancer Journal|December 13, 2018
Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcomeAshley R Paquin, Shaji K Kumar, Francis K Buadi, et al.
American Journal of Hematology|September 9, 2018
Utility and prognostic value of <sup>18</sup> F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myelomaMohammed A Aljama, M Hasib Sidiqi, Francis K Buadi, et al.
Blood|March 28, 2009
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasonePrashant Kapoor, Shaji Kumar, Rafael Fonseca, et al.
Leukemia|July 31, 2020
Correction: Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosisEli Muchtar, Morie A Gertz, Taxiarchis V Kourelis, et al.
European Journal of Haematology|March 8, 2020
c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myelomaAlessandra Di Bacco, Nizar J Bahlis, Nikhil C Munshi, et al.
American Journal of Hematology|December 29, 2018
Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry methodSurbhi Sidana, Dragan Jevremovic, Rhett P Ketterling, et al.
Blood|October 22, 2017
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patientsHervé Avet-Loiseau, Nizar J Bahlis, Wee-Joo Chng, et al.
Blood|January 28, 2017
Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early deathEli Muchtar, Morie A Gertz, Shaji K Kumar, et al.
Pageof 61